FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332029876> ?p ?o ?g. }

• W2332029876 endingPage "e706" @default.
• W2332029876 startingPage "e706" @default.
• W2332029876 abstract "To improve the outcome of allogeneic stem cell transplantation in refractory acute myeloid leukemia (AML), we conducted a single-arm phase II clinical trial to evaluate the efficacy and feasibility of conditioning regimen following cytoreduction chemotherapy with 7-day interval. Adult patients with refractory AML were enrolled in the study and received fludarabine, cytarabine, and idarubicin (FLAG-IDA) as cytoreductive chemotherapy followed by busulfan and fludarabine (Flu-BU) conditioning regimen and transfusion of mobilized peripheral stem cells from human leukocyte antigen-matched sibling or unrelated donor. The primary endpoint of the study was 2-year leukemia-free survival (LFS) and secondary endpoints included complete-remission rate, 2-year overall survival (OS), nonrelapse mortality (NRM), and relapse rate. A total of 16 patients were enrolled with median age of 36 (16–60), which included 9 primary induction failure, 2 early relapse, and 5 with relapse/refractory disease. The median cycles of previous chemotherapy were 4 (3–10) with a median of 55% (1%–90%) blasts in bone marrow. Six patients received transplantation from matched sibling and 10 from matched unrelated donors. After transplantation, 15 patients achieved bone marrow remission (11 complete remissions [CRs] and 4 bone marrow remissions without platelet recovery) at day +28. A total of 8 patients remained alive in CR with median LFS of 29.5 months (9.5–40.5 months). Four patients relapsed and 3 of them died of disease and another 4 patients died because of transplantation-related toxicity. The 2-year NRM and relapse rates were 25.0% ± 10.8% and 33.4% ± 13.8%, respectively with 2-year OS at 53.5% ± 13.1% and LFS at 50.0% ± 12.5%. Based on the Simon 2-stage design, 5 out of first eligible 14 patients remained leukemia-free for more than 2 years after allogeneic hematopoietic stem cell transplantation; thus, the null hypothesis of the study will be rejected and the study protocol is accepted as being warranted for further study. Based on the above data, our phase II study demonstrated that the sequential FLAG-IDA cytoreduction chemotherapy followed by Flu-BU conditioning regimen given at the hematological nadir was feasible and has sufficient activity to warrant further investigation prospectively with a larger patient sample (clinicaltrials.gov identifier: NCT01496547)." @default.
• W2332029876 created "2016-06-24" @default.
• W2332029876 creator A5025071259 @default.
• W2332029876 creator A5032471296 @default.
• W2332029876 creator A5063056426 @default.
• W2332029876 creator A5073803028 @default.
• W2332029876 date "2015-04-01" @default.
• W2332029876 modified "2023-09-26" @default.
• W2332029876 title "Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation" @default.
• W2332029876 cites W1594819241 @default.
• W2332029876 cites W1965763689 @default.
• W2332029876 cites W2011499718 @default.
• W2332029876 cites W2042888665 @default.
• W2332029876 cites W2053278212 @default.
• W2332029876 cites W2057015804 @default.
• W2332029876 cites W2061595804 @default.
• W2332029876 cites W2063563112 @default.
• W2332029876 cites W2066420284 @default.
• W2332029876 cites W2073525855 @default.
• W2332029876 cites W2077173355 @default.
• W2332029876 cites W2077684036 @default.
• W2332029876 cites W2078270553 @default.
• W2332029876 cites W2079801336 @default.
• W2332029876 cites W2082261439 @default.
• W2332029876 cites W2120707944 @default.
• W2332029876 cites W2127080762 @default.
• W2332029876 cites W2127630646 @default.
• W2332029876 cites W2143034151 @default.
• W2332029876 cites W2147773887 @default.
• W2332029876 cites W2320331489 @default.
• W2332029876 cites W2409904921 @default.
• W2332029876 cites W2618073389 @default.
• W2332029876 cites W70277491 @default.
• W2332029876 doi "https://doi.org/10.1097/md.0000000000000706" @default.
• W2332029876 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4602511" @default.
• W2332029876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25881847" @default.
• W2332029876 hasPublicationYear "2015" @default.
• W2332029876 type Work @default.
• W2332029876 sameAs 2332029876 @default.
• W2332029876 citedByCount "13" @default.
• W2332029876 countsByYear W23320298762016 @default.
• W2332029876 countsByYear W23320298762017 @default.
• W2332029876 countsByYear W23320298762018 @default.
• W2332029876 countsByYear W23320298762019 @default.
• W2332029876 countsByYear W23320298762020 @default.
• W2332029876 countsByYear W23320298762021 @default.
• W2332029876 countsByYear W23320298762022 @default.
• W2332029876 crossrefType "journal-article" @default.
• W2332029876 hasAuthorship W2332029876A5025071259 @default.
• W2332029876 hasAuthorship W2332029876A5032471296 @default.
• W2332029876 hasAuthorship W2332029876A5063056426 @default.
• W2332029876 hasAuthorship W2332029876A5073803028 @default.
• W2332029876 hasBestOaLocation W23320298761 @default.
• W2332029876 hasConcept C126322002 @default.
• W2332029876 hasConcept C141071460 @default.
• W2332029876 hasConcept C2776694085 @default.
• W2332029876 hasConcept C2776755627 @default.
• W2332029876 hasConcept C2777408962 @default.
• W2332029876 hasConcept C2778041864 @default.
• W2332029876 hasConcept C2779117419 @default.
• W2332029876 hasConcept C2779263901 @default.
• W2332029876 hasConcept C2780611847 @default.
• W2332029876 hasConcept C2781413609 @default.
• W2332029876 hasConcept C2911091166 @default.
• W2332029876 hasConcept C71924100 @default.
• W2332029876 hasConcept C90924648 @default.
• W2332029876 hasConceptScore W2332029876C126322002 @default.
• W2332029876 hasConceptScore W2332029876C141071460 @default.
• W2332029876 hasConceptScore W2332029876C2776694085 @default.
• W2332029876 hasConceptScore W2332029876C2776755627 @default.
• W2332029876 hasConceptScore W2332029876C2777408962 @default.
• W2332029876 hasConceptScore W2332029876C2778041864 @default.
• W2332029876 hasConceptScore W2332029876C2779117419 @default.
• W2332029876 hasConceptScore W2332029876C2779263901 @default.
• W2332029876 hasConceptScore W2332029876C2780611847 @default.
• W2332029876 hasConceptScore W2332029876C2781413609 @default.
• W2332029876 hasConceptScore W2332029876C2911091166 @default.
• W2332029876 hasConceptScore W2332029876C71924100 @default.
• W2332029876 hasConceptScore W2332029876C90924648 @default.
• W2332029876 hasIssue "15" @default.
• W2332029876 hasLocation W23320298761 @default.
• W2332029876 hasLocation W23320298762 @default.
• W2332029876 hasLocation W23320298763 @default.
• W2332029876 hasOpenAccess W2332029876 @default.
• W2332029876 hasPrimaryLocation W23320298761 @default.
• W2332029876 hasRelatedWork W1966354573 @default.
• W2332029876 hasRelatedWork W2038653121 @default.
• W2332029876 hasRelatedWork W2098356351 @default.
• W2332029876 hasRelatedWork W2324148918 @default.
• W2332029876 hasRelatedWork W2374949105 @default.
• W2332029876 hasRelatedWork W2391054219 @default.
• W2332029876 hasRelatedWork W2563097657 @default.
• W2332029876 hasRelatedWork W3032560561 @default.
• W2332029876 hasRelatedWork W3144137627 @default.
• W2332029876 hasRelatedWork W68423370 @default.
• W2332029876 hasVolume "94" @default.
• W2332029876 isParatext "false" @default.
• W2332029876 isRetracted "false" @default.

• next